Enspryng approved in Japan for neuromyelitis optica spectrum disorder

Japan’s Ministry of Health, Labour and Welfare approved Enspryng to treat adults and children with neuromyelitis optica spectrum disorder, according to a press release.
Enspryng (satralizumab, Roche) is approved for the prevention of neuromyelitis optica spectrum disorder (NMOSD) relapses in adults and children who are aquaporin-4 antibody seropositive. In two pivotal phase 3 studies, the drug showed efficacy and significantly reduced the risk for relapse. It was evaluated as monotherapy and as an addition to baseline immunosuppressant therapy.
“Today’s approval in Japan is

Full Story →